The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still down about 32% for the year. Moderna has more on the science behind mRNA. Copyright © 2025 HealthDay. All rights reserved.

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK in adults aged 50 years and older in a late-stage study, sending its shares up more than 2%.

Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for FDA approval and 2026 rollout.